Lyra Therapeutics (LYRA) Stock Forecast, Price Target & Predictions
LYRA Stock Forecast
Lyra Therapeutics stock forecast is as follows: an average price target of $0.50 (represents a 180.90% upside from LYRA’s last price of $0.18) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
LYRA Price Target
The average price target for Lyra Therapeutics (LYRA) is $0.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $0.50 to $0.50. This represents a potential 180.90% upside from LYRA's last price of $0.18.
LYRA Analyst Ratings
According to 5 Wall Street analysts, Lyra Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for LYRA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 3 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Lyra Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 07, 2024 | Dennis Ding | Jefferies | $0.50 | $0.52 | -4.12% | 180.90% |
The latest Lyra Therapeutics stock forecast, released on May 07, 2024 by Dennis Ding from Jefferies, set a price target of $0.50, which represents a -4.12% decrease from the stock price at the time of the forecast ($0.52), and a 180.90% increase from LYRA last price ($0.18).
Lyra Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $0.50 |
| Last Closing Price | $0.18 | $0.18 | $0.18 |
| Upside/Downside | -100.00% | -100.00% | 180.90% |
In the current month, the average price target of Lyra Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lyra Therapeutics's last price of $0.18. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Jun 20, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 20, 2024 | Jefferies | Buy | Buy | Hold |
| May 07, 2024 | Jefferies | Buy | Buy | Hold |
| May 07, 2024 | Jefferies | - | Hold | Downgrade |
| May 06, 2024 | BTIG | Buy | Neutral | Downgrade |
| May 06, 2024 | BTIG | Buy | Reduce | Downgrade |
| May 06, 2024 | William Blair | - | Market Perform | Downgrade |
| May 02, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Feb 07, 2023 | BTIG | Buy | Buy | Hold |
Lyra Therapeutics's last stock rating was published by H.C. Wainwright on Aug 15, 2024. The company gave LYRA a "Neutral" rating, the same as its previous rate.
Lyra Therapeutics Financial Forecast
Lyra Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $146.00K | $544.00K | $458.00K | $410.00K | $11.00K | $359.00K | $407.00K | $5.37M | $271.00K | $14.00K |
| Avg Forecast | $1.41M | $204.70K | $204.70K | $204.70K | $102.35K | $102.35K | $102.35K | $102.35K | $204.80K | $315.60K | $532.00K | $344.92K | $388.80K | $371.60K | $136.67K | $159.50K | $148.80K | $101.75K | $1.43M | $2.68M | $1.13M | $375.00K |
| High Forecast | $1.53M | $222.50K | $222.50K | $222.50K | $111.25K | $111.25K | $111.25K | $111.25K | $222.61K | $343.04K | $578.26K | $344.96K | $403.75K | $403.91K | $148.55K | $173.37K | $161.74K | $101.75K | $1.43M | $2.68M | $1.13M | $375.00K |
| Low Forecast | $1.23M | $178.00K | $178.00K | $178.00K | $89.00K | $89.00K | $89.00K | $89.00K | $178.09K | $274.43K | $462.61K | $344.88K | $373.85K | $323.13K | $118.84K | $138.69K | $129.39K | $101.75K | $1.43M | $2.68M | $1.13M | $375.00K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.38% | 1.46% | 3.35% | 2.57% | 0.07% | 3.53% | 0.28% | 2.00% | 0.24% | 0.04% |
Lyra Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $344.92K, with a low forecast of $344.88K, and a high forecast of $344.96K. LYRA's average Quarter revenue forecast represents a 136.24% increase compared to the company's last Quarter revenue of $146.00K (Dec 23).
Lyra Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-16.39M | $-16.83M | $-16.50M | $-17.03M | $-13.62M | $-14.55M | $-14.23M | $-6.75M | $-13.36M | $-10.73M |
| Avg Forecast | $-282.26K | $-40.94K | $-40.94K | $-40.94K | $-20.47K | $-20.47K | $-20.47K | $-20.47K | $-40.96K | $-63.12K | $-106.40K | $-68.98K | $-77.76K | $-74.32K | $-27.33K | $-31.90K | $-29.76K | $-20.35K | $-286.95K | $-8.50M | $-225.00K | $-75.00K |
| High Forecast | $-245.44K | $-35.60K | $-35.60K | $-35.60K | $-17.80K | $-17.80K | $-17.80K | $-17.80K | $-35.62K | $-54.89K | $-92.52K | $-68.97K | $-74.77K | $-64.63K | $-23.77K | $-27.74K | $-25.88K | $-20.35K | $-286.95K | $-6.80M | $-225.00K | $-75.00K |
| Low Forecast | $-306.80K | $-44.50K | $-44.50K | $-44.50K | $-22.25K | $-22.25K | $-22.25K | $-22.25K | $-44.52K | $-68.61K | $-115.65K | $-68.99K | $-80.75K | $-80.78K | $-29.71K | $-34.67K | $-32.35K | $-20.35K | $-286.95K | $-10.21M | $-225.00K | $-75.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 210.81% | 226.42% | 603.78% | 533.84% | 457.58% | 714.88% | 49.60% | 0.79% | 59.38% | 143.08% |
undefined analysts predict LYRA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lyra Therapeutics's previous annual EBITDA (undefined) of $NaN.
Lyra Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-15.16M | $-15.65M | $-15.62M | $-16.25M | $-14.23M | $-14.71M | $-14.42M | $-7.00M | $-13.34M | $-11.05M |
| Avg Forecast | $-24.73M | $-20.30M | $-14.79M | $-11.75M | $-6.87M | $-6.22M | $-6.87M | $-6.58M | $-8.35M | $-14.07M | $-21.88M | $-17.16M | $-20.62M | $-20.78M | $-27.71M | $-23.89M | $-27.10M | $-28.80M | $-24.41M | $-8.88M | $-51.66M | $-48.17M |
| High Forecast | $-20.54M | $-16.86M | $-12.28M | $-9.76M | $-5.71M | $-5.16M | $-5.71M | $-6.25M | $-7.65M | $-11.69M | $-18.17M | $-14.25M | $-15.00M | $-17.25M | $-23.01M | $-19.84M | $-22.51M | $-28.80M | $-24.41M | $-7.10M | $-51.66M | $-48.17M |
| Low Forecast | $-27.53M | $-22.60M | $-16.47M | $-13.08M | $-7.65M | $-6.92M | $-7.65M | $-6.90M | $-9.04M | $-15.66M | $-24.36M | $-19.10M | $-26.87M | $-23.13M | $-30.84M | $-26.59M | $-30.17M | $-28.80M | $-24.41M | $-10.65M | $-51.66M | $-48.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.74% | 0.75% | 0.56% | 0.68% | 0.53% | 0.51% | 0.59% | 0.79% | 0.26% | 0.23% |
Lyra Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LYRA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Lyra Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $4.36M | $5.00M | $4.57M | $5.13M | $4.40M | $5.14M | $4.13M | $3.89M | $3.57M | $4.02M |
| Avg Forecast | $21.72M | $3.15M | $3.15M | $3.15M | $1.58M | $1.58M | $1.58M | $1.58M | $3.15M | $4.86M | $8.19M | $5.31M | $5.98M | $5.72M | $2.10M | $2.45M | $2.29M | $1.57M | $22.08M | $41.30M | $17.32M | $5.77M |
| High Forecast | $23.61M | $3.42M | $3.42M | $3.42M | $1.71M | $1.71M | $1.71M | $1.71M | $3.43M | $5.28M | $8.90M | $5.31M | $6.21M | $6.22M | $2.29M | $2.67M | $2.49M | $1.57M | $22.08M | $41.30M | $17.32M | $5.77M |
| Low Forecast | $18.89M | $2.74M | $2.74M | $2.74M | $1.37M | $1.37M | $1.37M | $1.37M | $2.74M | $4.22M | $7.12M | $5.31M | $5.75M | $4.97M | $1.83M | $2.13M | $1.99M | $1.57M | $22.08M | $41.30M | $17.32M | $5.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 0.87% | 2.17% | 2.09% | 1.92% | 3.28% | 0.19% | 0.09% | 0.21% | 0.70% |
Lyra Therapeutics's average Quarter SG&A projection for Mar 24 is $5.31M, based on 1 Wall Street analysts, with a range of $5.31M to $5.31M. The forecast indicates a 21.85% rise compared to LYRA last annual SG&A of $4.36M (Dec 23).
Lyra Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.26 | $-0.27 | $-0.00 | $-0.44 | $-0.47 | $-0.40 | $-0.42 | $-0.54 | $-1.03 | $-0.85 |
| Avg Forecast | $-0.38 | $-0.31 | $-0.23 | $-0.18 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.13 | $-0.21 | $-0.33 | $-0.26 | $-0.32 | $-0.32 | $-0.42 | $-0.36 | $-0.41 | $-0.44 | $-0.37 | $-0.06 | $-0.79 | $-0.74 |
| High Forecast | $-0.31 | $-0.26 | $-0.19 | $-0.15 | $-0.09 | $-0.08 | $-0.09 | $-0.10 | $-0.12 | $-0.18 | $-0.28 | $-0.22 | $-0.23 | $-0.26 | $-0.35 | $-0.30 | $-0.34 | $-0.44 | $-0.37 | $-0.06 | $-0.79 | $-0.74 |
| Low Forecast | $-0.42 | $-0.35 | $-0.25 | $-0.20 | $-0.12 | $-0.11 | $-0.12 | $-0.11 | $-0.14 | $-0.24 | $-0.37 | $-0.29 | $-0.41 | $-0.35 | $-0.47 | $-0.41 | $-0.46 | $-0.44 | $-0.37 | $-0.06 | $-0.79 | $-0.74 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.83% | 0.85% | 0.00% | 1.21% | 1.14% | 0.91% | 1.13% | 9.82% | 1.31% | 1.16% |
According to undefined Wall Street analysts, Lyra Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LYRA previous annual EPS of $NaN (undefined).
Lyra Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.20 | $10.00 | 733.33% | Buy |
| CTMX | CytomX Therapeutics | $0.87 | $5.73 | 558.62% | Buy |
| TIL | Instil Bio | $23.36 | $78.25 | 234.97% | Hold |
| AUTL | Autolus Therapeutics | $2.80 | $8.87 | 216.79% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.62 | $38.80 | 184.88% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| NUVB | Nuvation Bio | $2.58 | $6.75 | 161.63% | Buy |
| CGEM | Cullinan Oncology | $12.58 | $31.50 | 150.40% | Buy |
| ASMB | Assembly Biosciences | $15.02 | $35.50 | 136.35% | Buy |
| NXTC | NextCure | $1.30 | $3.00 | 130.77% | Buy |
| ACHL | Achilles Therapeutics | $1.07 | $2.00 | 86.92% | Buy |
| BOLT | Bolt Biotherapeutics | $0.57 | $1.00 | 75.44% | Hold |